Biotech Startups

Dermala is a skincare company offering a personalized, FDA-approved acne treatment delivered as a monthly subscription kit that uses probiotics, prebiotics, and postbiotics to target acne-causing bacteria in the skin and gut microbiome. It applies big data, machine learning, and AI to tailor and optimize each customer's treatment based on their results.

3 investors

AMR Bio is a clinical-phase biotechnology company developing novel anti-infective drugs focused on infection prevention and combating antibiotic resistance.

3 investors

Detect develops a point-of-care molecular diagnostics platform for women's health applications. The company brings laboratory-quality testing capabilities to clinical settings closer to patients.

3 investors

Diag-Nose.io develops precision diagnostics and therapies for respiratory diseases including asthma, COPD, and sinusitis by combining nasal microsampling, proteomics, and machine learning to analyze airway biology. The company serves respiratory specialists, biotech companies, pharmaceutical firms, and researchers.

3 investors

Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds. It brings together clinical researchers and pharmaceutical development experts to advance early-stage candidates for mood and related disorders.

3 investors

Diptera.ai uses computer vision and insect biology to control pest populations without pesticides, starting with mosquitoes. The company has demonstrated field-tested effectiveness in reducing mosquito numbers in Israel and plans expansion to African regions.

3 investors

Ditto Bio uses AI to identify protein candidates from parasites and pathogens for treating autoimmune diseases. The company mines natural compounds from viruses, ticks, and worms whose immune-modulating properties have evolved over millions of years.

3 investors

DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.

3 investors

Dorian Therapeutics develops therapeutics aimed at rejuvenating tissue and treating age-related diseases. The company operates in the biotech and anti-aging therapeutics space.

3 investors

Dot Ingredients develops particle surfactant technology to support climate change mitigation efforts. The company is a research-focused organization based in Auckland, New Zealand with connections to Auckland University of Technology.

3 investors

Dotomics builds foundation models for biology using AI and machine learning. The company serves researchers and organizations in the biotechnology and life sciences sectors.

3 investors

DP Technology develops AI for Science tools and intelligent systems for scientific discovery, including its Uni-Fold/宇知 science discovery engine, computation and simulation software (Hermite, Piloteye), and the Bohrium research platform. It serves scientists and R&D organizations in fields such as life sciences and materials science.

3 investors

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.

3 investors

Dreamfold engineers proteins as therapeutic medicines, using generative AI models that reason over protein sequence and structure to enable potent, localized immune modulation with minimal off-target effects.

3 investors

Droplet Biosciences develops cancer diagnostics with a focus on liquid biopsy and precision oncology. The company works in the molecular diagnostics space for cancer detection and personalized medicine.

3 investors

Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.

3 investors

3 investors

EBT Medical develops neuromodulation technologies targeting the Saphenous nerve to treat pelvic health disorders, particularly overactive bladder. The clinical-stage company, spun out of the University of Toronto, is advancing paradigm-shifting medical devices for patients with pelvic health conditions.

3 investors

ECBF is a venture capital firm specializing in Europe's bioeconomy and circular economy, investing in companies across industries including food, agriculture, and materials that combine strong economic returns with systemic environmental impact. The firm manages €300 million and focuses on scaling pioneering founders building climate-neutral and regenerative solutions aligned with European environmental goals.

3 investors

Eden Brew develops food and supplementation products designed to deliver nutrition in natural forms that align with how the human body processes nutrients, with a focus on sustainable scaling and long-term health support.

3 investors

Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases. Its pipeline targets conditions such as Acute Respiratory Distress Syndrome (ARDS) by modulating immune pathways implicated across multiple diseases.

3 investors

Hospital-based therapies for acute, life-threatening neurological conditions. (NASDAQ: EDGE)

3 investors

EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.

3 investors

Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.

3 investors